Related Experiment Video
Updated: Oct 21, 2025
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.7K
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Xin Zhao1, Minghe Wang1, Zhitong Wen1
1Department of Pharmacology, Shanxi Medical University, Taiyuan, China.
Frontiers in Endocrinology
|September 9, 2021
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer benefits beyond type 2 diabetes management, including weight loss and islet cell protection. These agents also show promise for neuroprotection, cardiovascular health, and metabolic regulation, with ongoing research into their role in tumorigenesis.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Glucagon-like peptide-1 (GLP-1) is a key incretin hormone.
- GLP-1 receptor agonists (GLP-1RAs) are established treatments for type 2 diabetes (T2DM).
- GLP-1RAs offer benefits including weight loss, islet cell protection, and minimal side effects.
Purpose of the Study:
- To review the therapeutic effects and mechanisms of GLP-1RAs.
- To explore the correlation of GLP-1RAs with nervous, cardiovascular, and endocrine systems.
- To examine the relationship between GLP-1RAs, metabolism, and tumorigenesis.
Main Methods:
- Literature review of studies on GLP-1 receptor agonists.
- Analysis of biological effects across multiple organ systems.
- Investigation into the role of GLP-1RAs in disease contexts including T2DM and cancer.
Main Results:
- GLP-1R is expressed in various tissues, mediating diverse effects.
- GLP-1RAs demonstrate neuroprotective, cardiovascular, and metabolic regulatory functions.
- Emerging evidence links GLP-1RAs to tumorigenesis, development, and prognosis in T2DM patients.
Conclusions:
- GLP-1RAs possess broad therapeutic potential beyond glycemic control.
- Their multifaceted actions impact nervous, cardiovascular, and endocrine health.
- Further research is warranted on GLP-1RAs' complex relationship with metabolism and cancer.
More Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
487
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
487
01:06Oral Hypoglycemic Agents: Glinides
311
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
311
01:23Dipeptidyl Peptidase 4 Inhibitors
298
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
298
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
326
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
326
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
349
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
349
01:16Hormones Regulating Blood Glucose
5.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
5.0K